Terms: = Leukemia AND RUNX1, PEBP2A2, 861, ENSG00000159216, Q01196, AML1, CBFA2, AMLCR1 AND Clinical Outcome
68 results:
1. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
Ozga M; Nicolet D; Mrózek K; Yilmaz AS; Kohlschmidt J; Larkin KT; Blachly JS; Oakes CC; Buss J; Walker CJ; Orwick S; Jurinovic V; Rothenberg-Thurley M; Dufour A; Schneider S; Sauerland MC; Görlich D; Krug U; Berdel WE; Woermann BJ; Hiddemann W; Braess J; Subklewe M; Spiekermann K; Carroll AJ; Blum WG; Powell BL; Kolitz JE; Moore JO; Mayer RJ; Larson RA; Uy GL; Stock W; Metzeler KH; Grimes HL; Byrd JC; Salomonis N; Herold T; Mims AS; Eisfeld AK
Leukemia; 2024 Jan; 38(1):45-57. PubMed ID: 38017103
[TBL] [Abstract] [Full Text] [Related]
2. Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome.
Pastore F; Gittinger H; Raab S; Tschuri S; Ksienzyk B; Konstandin NP; Schneider S; Rothenberg-Thurley M; Horny HP; Werner M; Sauerland MC; Amler S; Görlich D; Berdel WE; Wörmann B; Braess J; Hiddemann W; Tischer J; Herold T; Metzeler KH; Spiekermann K
Br J Haematol; 2023 Sep; 202(6):1165-1177. PubMed ID: 37455345
[TBL] [Abstract] [Full Text] [Related]
3. Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome.
Salz L; Seitz A; Schäfer D; Franzen J; Holzer T; Garcia-Prieto CA; Bürger I; Hardt O; Esteller M; Wagner W
Leukemia; 2023 Sep; 37(9):1868-1878. PubMed ID: 37452103
[TBL] [Abstract] [Full Text] [Related]
4. The clinical phenotype of germline runx1 mutations in relation to the accompanying somatic variants and runx1 isoform expression.
Cabrerizo Granados D; Barbosa I; Baliakas P; Hellström-Lindberg E; Lundin V
Genes Chromosomes Cancer; 2023 Nov; 62(11):672-677. PubMed ID: 37303296
[TBL] [Abstract] [Full Text] [Related]
5. LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study.
Vasseur L; Fenwarth L; Lambert J; de Botton S; Figeac M; Villenet C; Heiblig M; Dumas PY; Récher C; Berthon C; Lemasle E; Lebon D; Lambert J; Terré C; Celli-Lebras K; Dombret H; Preudhomme C; Cheok M; Itzykson R; Duployez N
Blood Adv; 2023 Aug; 7(15):4024-4034. PubMed ID: 37205853
[TBL] [Abstract] [Full Text] [Related]
6. Somatic Exonic Deletions in runx1 Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid leukemia.
Eriksson A; Engvall M; Mathot L; Österroos A; Rippin M; Cavelier L; Ladenvall C; Baliakas P
Clin Cancer Res; 2023 Aug; 29(15):2826-2834. PubMed ID: 37022349
[TBL] [Abstract] [Full Text] [Related]
7. Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication.
Liu Y; Klein J; Bajpai R; Dong L; Tran Q; Kolekar P; Smith JL; Ries RE; Huang BJ; Wang YC; Alonzo TA; Tian L; Mulder HL; Shaw TI; Ma J; Walsh MP; Song G; Westover T; Autry RJ; Gout AM; Wheeler DA; Wan S; Wu G; Yang JJ; Evans WE; Loh M; Easton J; Zhang J; Klco JM; Meshinchi S; Brown PA; Pruett-Miller SM; Ma X
Nat Commun; 2023 Apr; 14(1):1739. PubMed ID: 37019972
[TBL] [Abstract] [Full Text] [Related]
8. Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes.
Konishi T; Sadato D; Toya T; Hirama C; Kishida Y; Nagata A; Yamada Y; Shingai N; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Okuyama Y; Harada H; Ohashi K; Harada Y; Doki N
Sci Rep; 2023 Feb; 13(1):2641. PubMed ID: 36788335
[TBL] [Abstract] [Full Text] [Related]
9. SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis.
Huber S; Haferlach T; Meggendorfer M; Hutter S; Hoermann G; Baer C; Kern W; Haferlach C
Leukemia; 2022 Dec; 36(12):2894-2902. PubMed ID: 36261576
[TBL] [Abstract] [Full Text] [Related]
10. HOXA9 has the hallmarks of a biological switch with implications in blood cancers.
Talarmain L; Clarke MA; Shorthouse D; Cabrera-Cosme L; Kent DG; Fisher J; Hall BA
Nat Commun; 2022 Oct; 13(1):5829. PubMed ID: 36192425
[TBL] [Abstract] [Full Text] [Related]
11. Acute myeloid leukemia patients with variant or unusual translocations involving chromosomes 8 and 21 - A comprehensive cytogenetic profiling of three cases with review of literature.
Akhila Raj TV; Gopinath P; Geetha Raj JA; Narayanan G; Nair SG; Joy Philip DS; Raveendran S; Geetha P; Sreedharan H
J Cancer Res Ther; 2022; 18(3):697-703. PubMed ID: 35900542
[TBL] [Abstract] [Full Text] [Related]
12. [Prognostic factors of autologous hematopoietic stem cell transplantation in intermediate-risk acute myeloid leukemia patients with minimal residual disease negativity].
Lian JY; Ye PP; Cao JJ; Chen D; Wang TT; Si T; Yuan JJ; Lu Y
Zhonghua Nei Ke Za Zhi; 2022 Jun; 61(6):673-677. PubMed ID: 35673748
[TBL] [Abstract] [Full Text] [Related]
13. The association of complex genetic background with the prognosis of acute leukemia with ambiguous lineage.
Huang J; Zhou J; Xiao M; Mao X; Zhu L; Liu S; Li Q; Wang J; Zhou J; Cai H; Wang G
Sci Rep; 2021 Dec; 11(1):24290. PubMed ID: 34934076
[TBL] [Abstract] [Full Text] [Related]
14. runx1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia.
Masuda T; Maeda S; Shimada S; Sakuramoto N; Morita K; Koyama A; Suzuki K; Mitsuda Y; Matsuo H; Kubota H; Kato I; Tanaka K; Takita J; Hirata M; Kataoka TR; Nakahata T; Adachi S; Hirai H; Mizuta S; Naka K; Imai Y; Kimura S; Sugiyama H; Kamikubo Y
Cancer Sci; 2022 Feb; 113(2):529-539. PubMed ID: 34902205
[TBL] [Abstract] [Full Text] [Related]
15. clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia.
Yu T; Chi J; Wang L
Hematology; 2021 Dec; 26(1):848-859. PubMed ID: 34674615
[TBL] [Abstract] [Full Text] [Related]
16. Effective therapy for AML with runx1 mutation by cotreatment with inhibitors of protein translation and BCL2.
Mill CP; Fiskus W; DiNardo CD; Birdwell C; Davis JA; Kadia TM; Takahashi K; Short N; Daver N; Ohanian M; Borthakur G; Kornblau SM; Green MR; Qi Y; Su X; Khoury JD; Bhalla KN
Blood; 2022 Feb; 139(6):907-921. PubMed ID: 34601571
[TBL] [Abstract] [Full Text] [Related]
17. Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification.
van der Werf I; Wojtuszkiewicz A; Meggendorfer M; Hutter S; Baer C; Heymans M; Valk PJM; Kern W; Haferlach C; Janssen JJWM; Ossenkoppele GJ; Cloos J; Haferlach T
Blood Adv; 2021 Sep; 5(17):3254-3265. PubMed ID: 34448812
[TBL] [Abstract] [Full Text] [Related]
18. Genetic features and efficacy of decitabine-based chemotherapy in elderly patients with acute myeloid leukemia.
Wang B; Guan W; Lv N; Li T; Yu F; Huang Y; Wang Y; Li L; Yu L
Hematology; 2021 Dec; 26(1):371-379. PubMed ID: 33971800
[TBL] [Abstract] [Full Text] [Related]
19. Distinct association of RUNX family expression with genetic alterations and clinical outcome in acute myeloid leukemia.
Zhao Y; Zhang T; Zhao Y; Zhou J
Cancer Biomark; 2020; 29(3):387-397. PubMed ID: 32741803
[TBL] [Abstract] [Full Text] [Related]
20. Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse.
Onecha E; Rapado I; Luz Morales M; Carreño-Tarragona G; Martinez-Sanchez P; Gutierrez X; Sáchez Pina JM; Linares M; Gallardo M; Martinez-López J; Ayala R
Haematologica; 2021 Sep; 106(9):2325-2333. PubMed ID: 32732356
[TBL] [Abstract] [Full Text] [Related]
[Next]
